On Friday, Shares of AEGON N.V. (ADR)(NYSE:AEG), added 2.12% and closed at $3.86 in the last trading session. The last trading range of the stock ranges between $3.80 and $3.88. Aegon will repurchase 30,765,224 common shares to neutralize the dilutive effect of the 2016 interim stock dividend. These shares will be held as treasury shares and will be used to pay future stock dividends.
Aegon is committed to the repurchase of the common shares by engaging a third party to execute the transactions on its behalf. These transactions will begin on October 3, 2016, and are expected to be accomplished on or before November 11, 2016. The common shares will be repurchased at a maximum of the daily volume-weighted average price. Aegon will provide weekly updates regarding the transactions.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), jumped 2.60% and closed at $87.21 in the last trading session. The last trading range of the stock ranges between $83.50 and $88.91. The company’s Market capitalization is $22.17 Billion with the total Outstanding Shares of 247.78 million. Vertex Pharmaceuticals Incorporated (VRTX) recently declared that the U.S. Food and Drug Administration (FDA) approved ORKAMBI® (lumacaftor/ivacaftor) for use in children with cystic fibrosis (CF) ages 6 through 11 who have two copies of the F508del mutation. People with this mutation represent the leading population of those with CF, a rare, life-threatening disease. ORKAMBI is the first and only medicine to treat the underlying cause of CF for people with this mutation. It was formerly approved by the FDA for use in people ages 12 and older with two copies of the F508del mutation. With recently’s approval, about 11,000 people with CF are eligible for treatment with ORKAMBI in the United States. ORKAMBI will be available for eligible children ages 6 through 11 in the United States as soon as possible. Vertex also recently lowered its guidance for 2016 ORKAMBI revenues to a range of $950 million to $990 million.
“The ability to treat children as young as six who have the most common form of the disease is an important milestone as we pursue our aim to develop medicines for all people with CF,” said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical Officer at Vertex. “We believe it is important to treat the underlying cause of the disease as early as possible in these patients.”
The approval is based on data from a formerly declared open-label Phase 3 clinical safety study of ORKAMBI presented at the 39th European Cystic Fibrosis Society Conference in June 2016. These data will be presented at the 30th Annual North American Cystic Fibrosis Conference October 27-29 in Orlando, Florida.
Cerner Corporation (NASDAQ:CERN), jumped 0.36% and closed at $61.75in the last trading session. The last trading range of the stock ranges between $61.19 and $62.06. During the 52-week trading session the minimum price at which share price traded, registered at $49.59 and reached to max level of $68.31. Miami Children’s Health System (MCHS) and its associates, Pediatric Specialists of America and Nicklaus Children’s Hospital, have expanded their relationship with Cerner, a global leader in health care technology. Through its Business Office Services (BOS) offering, Cerner will manage professional revenue cycle administration across the health system’s 200-member employed physician group practice.
In conjunction with the existing systemwide Cerner Millennium® electronic health record (EHR) and billing platforms, BOS is designed to facilitate Pediatric Specialists of America to create operational efficiencies and improve financial communication with patients.
“Our long-term engagement with Cerner has already assisted our health system achieve multiple clinical and financial aims, and we are optimistic about expanding our relationship,” said Edward Martinez, senior vice president and CIO, Miami Children’s Health System. “When it was time to re-evaluate our ambulatory revenue cycle processes, we believe that Cerner Business Office Services can assist us achieve success among our growing pediatric provider community.”
Cerner’s BOS provides holistic and proactive revenue cycle administration services at practices of all sizes and specialties. In addition to claims process and denial administration optimization, Cerner’s billing experts leverage best practices and learnings from continuous analysis to improve upon their own performance.